A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older

PHASE4CompletedINTERVENTIONAL
Enrollment

767

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Influenza
Interventions
BIOLOGICAL

Fluad_MF59-adjuvanted trivalent influenza subunit vaccine

BIOLOGICAL

Vantaflu_MF59-adjuvanted trivalent influenza subunit vaccine

Trial Locations (23)

415-040

KeeTaek Kim internal medicine Clinic, Gimpo-si

580-060

Jiguchon internal medicine Clinic, Jeongeup

530-390

21th Century hana internal medicine clinic, Mokpo

540-150

JoongAng family medicine Clinic, Suncheon

120-752

Yonsei Universtity College of Medicine, Sinchon-dong

Yonsei University Severance Hospital, Seoul

300-110

Hangajok internal medicine clinic, Daejeon

305-313

Ju Saengmyeong internal medicine Clinic, Daejeon

306-010

Daejeon hospital, Daejeon

770-160

SaeSeoul internal medicine and radiology Clinic, Daejeon

404-190

SeoIncheon catholic clinic, Incheon

405-224

TaeIl Jang internal medicine Clinic, Incheon

407-806

SeokYeon Kim internal medicine clinic, Incheon

110-744

Seoul National University Hospital, Seoul

131-865

Seoul medical center, Seoul

135-271

Global care internal medicine clinic, Seoul

138-201

Yeonsei Koum internal medicine Clinic, Seoul

140-887

Soon Chun Hyang University Hospital, Seoul

143-203

Gikim internal medicine clinic, Seoul

143-210

Lee internal medicine clinic, Seoul

150-950

Kangnam Sacred Heart Hospital, Seoul

Unknown

Korea University Guro Hospital, Seoul

Yonsei University Severance Hospital, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY